# OnCo record prostate-low-risk (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/prostate-low-risk/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "prostate-low-risk" ;
  schema:name "Localised prostate cancer, very low and low risk"@en ;
  schema:alternateName "Low-risk prostate cancer"@en, "Very low risk prostate cancer"@en, "Grade Group 1 prostate cancer"@en, "NCCN very low and low risk"@en, "Cambridge Prognostic Group 1"@en, "CPG 1"@en, "CPG1 prostate cancer"@en, "Grade group 1 prostate cancer"@en ;
  schema:description "Low-risk prostate cancer is Grade Group 1 disease confined to the gland with a PSA under 10. It grows so slowly that watching it closely is the recommended first choice, and most men who choose surveillance never need treatment."@en ;
  schema:url <https://onco.cc/cancers/prostate-low-risk/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Active_surveillance_of_prostate_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Active_surveillance_of_prostate_cancer>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459>, <https://www.nice.org.uk/guidance/ng131/chapter/Recommendations>, <https://www.rcpath.org/static/8cc88604-2c8d-4df4-a99542df41c102af/G084-dataset-for-histopathology-reports-for-prostatic-carcinoma.pdf> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/prostate-intermediate-risk/>, <https://onco.cc/cancers/prostate-high-risk/>, <https://onco.cc/cancers/prostate-bcr/>, <https://onco.cc/cancers/prostate-ductal-adenocarcinoma/> ;
  onco:terms <https://onco.cc/terms/cambridge-prognostic-group/>, <https://onco.cc/terms/percentage-gleason-pattern-4/>, <https://onco.cc/terms/cribriform-prostate-cancer/>, <https://onco.cc/terms/psa-density/>, <https://onco.cc/terms/watchful-waiting/>, <https://onco.cc/terms/tnm-prostate-cancer/>, <https://onco.cc/terms/lead-time-bias/>, <https://onco.cc/terms/overtreatment/>, <https://onco.cc/terms/number-needed-to-screen/>, <https://onco.cc/terms/pi-rads/>, <https://onco.cc/terms/template-mapping-biopsy/>, <https://onco.cc/terms/polygenic-risk-score/>, <https://onco.cc/terms/whole-mount-pathology/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-damico-risk-groups-jama-1998/>, <https://onco.cc/key-papers/paper-protect-15-year-nejm-2023/>, <https://onco.cc/key-papers/paper-klotz-active-surveillance-jco-2015/>, <https://onco.cc/key-papers/paper-precision-mri-targeted-biopsy-nejm-2018/> ;
  onco:pipeline <https://onco.cc/drugs/artera-ai-prostate/>, <https://onco.cc/drugs/decipher-prostate/>, <https://onco.cc/technologies/mp-mri/> ;
  onco:standardOfCare <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/trials/protect/>, <https://onco.cc/technologies/mp-mri/>, <https://onco.cc/terms/psa/>, <https://onco.cc/terms/gleason-grade-group/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/trials/chhip/>, <https://onco.cc/trials/pace-b/>, <https://onco.cc/technologies/mp-mri/>, <https://onco.cc/trials/precision-mri/>, <https://onco.cc/drugs/decipher-prostate/>, <https://onco.cc/drugs/artera-ai-prostate/> .